MURA — Mural Oncology Income Statement
0.000.00%
Last trade - 00:00- $35.86m
- -$41.23m
Annual income statement for Mural Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 175 | 185 | 196 | 138 |
| Operating Profit | -175 | -185 | -196 | -138 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -175 | -185 | -195 | -129 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -175 | -190 | -207 | -129 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -175 | -190 | -207 | -129 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -175 | -190 | -207 | -129 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -10.5 | -11.4 | -12.4 | -7.58 |